Search

Your search keyword '"Bardi, E."' showing total 3 results
Start Over Author "Bardi, E." Topic 0302 clinical medicine
3 results on '"Bardi, E."'

1. Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium

Author

Clemens, Eva, Van den Heuvel - Eibrink, Marry, Mulder, RL, Kremer, LCM (Leontien), Hudson, MM, Skinner, R, Constine, LS, Bass, JK, Kuehni, CE, Langer, T, van Dalen, EC, Bardi, E, Bonne, NX, Brock, PR, Brooks, B, Carleton, B, Caron, E, Chang, KW, Johnston, K, Knight, K, Nathan, PC, Orgel, E, Prasad, PK, Rottenberg, J, Scheinemann, K, de Vries, A.C.H., Walwyn, T, Weiss, A, Zehnhoff-Dinnesen, AA, Cohn, RJ, Landier, W, Kadan-Lottick, N, Levitt, G, Hoetink, A, Mussman, J, Princess Máxima Center for Pediatric Oncology [Utrecht, Netherlands], Erasmus MC-Sophia Hospital [Rotterdam, Netherlands], Emma Children's Hospital [Amsterdam, Netherlands] (Academic Medical Center), University of Amsterdam [Amsterdam] (UvA), St Jude Children's Research Hospital, Great North Children’s Hospital [Newcastle Upon Tyne, UK], Northern Institute for Cancer Research [Newcastle] (NICR), Newcastle University [Newcastle], University of Rochester Medical Center (URMC), Institute of Social and Preventive Medicine [Bern] (ISPM), Universität Bern [Bern] (UNIBE), University Hospital for Children and Adolescents [Lübeck, Germany], Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 (PRISM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'Otologie et d'Otoneurologie [CHU Lille], Centre Hospitalier Universitaire de Lille (CHU de Lille), Great Ormond Street Hospital for Children NHS Foundation Trust [London, UK] (GOSHC), University of British Columbia (UBC), Stanford University, Sydney Children's hospital, Oregon Health and Science University [Portland] (OHSU), The Hospital for sick children [Toronto] (SickKids), Children’s Hospital Los Angeles [Los Angeles], University of Southern California (USC), Louisiana State University (LSU), Children's Hospital at New Orleans, Masaryk University [Brno] (MUNI), Kantonsspital Aarau [Aarau, Switzerland], University Hospital Basel [Basel], McMaster University [Hamilton, Ontario], Perth Children's Hospital [Nedlands, WA, Australia], The University of Western Australia (UWA), University of Regensburg, University Hospital Münster - Universitaetsklinikum Muenster [Germany] (UKM), University of New South Wales [Sydney] (UNSW), University of Alabama at Birmingham [ Birmingham] (UAB), SALZET, Michel, Pediatrics, Universität Bern [Bern], Université de Lille-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), and Great Ormond Street Hospital for Children NHS Foundation Trust [London, UK]

Subjects
Shunt placement, Pediatrics, medicine.medical_specialty, Adolescent, [SDV]Life Sciences [q-bio], Childhood cancer, Harmonization, Antineoplastic Agents, Platinum Compounds, Article, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Ototoxicity, SDG 3 - Good Health and Well-being, Cancer Survivors, Neoplasms, otorhinolaryngologic diseases, Medicine, Humans, Young adult, 030223 otorhinolaryngology, Child, Evidence-Based Medicine, business.industry, Cancer, Guideline, medicine.disease, 3. Good health, [SDV] Life Sciences [q-bio], Oncology, 030220 oncology & carcinogenesis, Population Surveillance, Cranial Irradiation, business, Delivery of Health Care
Abstract

International audience; Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems—such as speech and language, social–emotional development, and learning difficulties—for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.

Published
2019
Full Text
View/download PDF

2. Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia

Author

Liv Andrés-Jensen, Andishe Attarbaschi, Edit Bardi, Shlomit Barzilai-Birenboim, Deepa Bhojwani, Melanie M Hagleitner, Christina Halsey, Arja Harila-Saari, Raphaele R L van Litsenburg, Melissa M Hudson, Sima Jeha, Motohiro Kato, Leontien Kremer, Wojciech Mlynarski, Anja Möricke, Rob Pieters, Caroline Piette, Elizabeth Raetz, Leila Ronceray, Claudia Toro, Maria Grazia Valsecchi, Lynda M Vrooman, Sigal Weinreb, Naomi Winick, Kjeld Schmiegelow, Madeline R Adams, Liv Andres-Jensen, Katja Baust, Tineke Boesten, Gabriele Calaminus, Rachel Conyers, Anne-Sophie Darlington, Maëlle de Ville, Gabriele Escherich, Melanie Hagleitner, Jen-Yin Hou, Ting-Huan Huang, Melissa Hudson, Meriel Jenney, Maryna Krawczuk-Rybak, Leontine Kremer, Melchior Lautem, Hse-Che Liu, Elixabet Lopez Lopez, Marion Mateos, Katarzyna Muszynska-Roslan, Riitta Niinimaki, Toby Trahair, Inge van der Sluis, Raphaële van Litsenburg, Lynda Vrooman, Andreas Wiener, Michihiro Yano, Ting-Chi Yeh, Ester Zapotocka, Andres-Jensen, L, Attarbaschi, A, Bardi, E, Barzilai-Birenboim, S, Bhojwani, D, Hagleitner, M, Halsey, C, Harila-Saari, A, van Litsenburg, R, Hudson, M, Jeha, S, Kato, M, Kremer, L, Mlynarski, W, Moricke, A, Pieters, R, Piette, C, Raetz, E, Ronceray, L, Toro, C, Valsecchi, M, Vrooman, L, Weinreb, S, Winick, N, and Schmiegelow, K

Subjects
medicine.medical_specialty, Activities of daily living, MEDLINE, Antineoplastic Agents, Blindness, Antineoplastic Agent, 03 medical and health sciences, 0302 clinical medicine, Refractory, Physicians, Medicine, Humans, Acute lymphocytic leukaemia, Renal Insufficiency, Intensive care medicine, Child, Hearing Loss, Hearing Lo, Severe toxicity, MED/01 - STATISTICA MEDICA, business.industry, Cancer, Hematology, Hematologic Disease, Precursor Cell Lymphoblastic Leukemia-Lymphoma, medicine.disease, Hematologic Diseases, Progression-Free Survival, Blindne, Clinical trial, Transplantation, Physician, 030220 oncology & carcinogenesis, business, Human, 030215 immunology
Abstract

5-year overall survival rates have surpassed 90% for childhood acute lymphocytic leukaemia, but survivors are at risk for permanent health sequelae. Although event-free survival appropriately represents the outcome for cancers with poor overall survival, this metric is inadequate when cure rates are high but challenged by serious, persistent complications. Accordingly, a group of experts in paediatric haematology-oncology, representative of 17 international acute lymphocytic leukaemia study groups, launched an initiative to construct a measure, designated severe toxicity-free survival (STFS), to quantify the occurrence of physician-prioritised toxicities to be integrated with standard cancer outcome reporting. Five generic inclusion criteria (not present before cancer diagnosis, symptomatic, objectifiable, of unacceptable severity, permanent, or requiring unacceptable treatments) were used to assess 855 health conditions, which resulted in inclusion of 21 severe toxicities. Consensus definitions were reached through a modified Delphi process supplemented by two additional plenary meetings. The 21 severe toxicities include severe adverse health conditions that substantially affect activities of daily living and are refractory to therapy (eg, refractory seizures), are without therapeutic options (eg, blindness), or require substantially invasive treatment (eg, cardiac transplantation). Incorporation of STFS assessment into clinical trials has the potential to improve and diversify treatment strategies, focusing not only on traditional outcome events and overall survival but also the frequencies of the most severe toxicities. The two major aims of this Review were to: prioritise and define unacceptable long-term toxicity for patients with childhood acute lymphocytic leukaemia, and define how these toxicities should be combined into a composite quantity to be integrated with other reported outcomes. Although STFS quantifies the clinically unacceptable health tradeoff for cure using childhood acute lymphocytic leukaemia as a model disease, the prioritised severe toxicities are based on generic considerations of relevance to any other cancer diagnosis and age group.

Published
2021

3. Long-term survivors of childhood cancer: cure and care—the Erice Statement (2006) revised after 10 years (2016)

Author

Roderick Skinner, Riccardo Haupt, Gisela Michel, Katie Rizvi, Andrea Biondi, Monica Terenziani, Helena J.H. van der Pal, Gabriele Calaminus, participants in PanCare, Michael M. Hawkins, Julianne Byrne, J. D. Beck, Stanislaw Garwicz, Martin Schrappe, Lars Hjorth, Meriel Jenney, Gregory H. Reaman, John J. Spinetta, Edit Bardi, Kevin C. Oeffinger, Eva Frey, Herwig Lackner, Leontien C. M. Kremer, Gerlind Bode, Jaap den Hartogh, Melissa M. Hudson, Claudia E. Kuehni, Momcilo Jankovic, Florent de Vathaire, Gill Levitt, Maria Grazia Valsecchi, Desiree Grabow, Jankovic, M, Haupt, R, Spinetta, J, Beck, J, Byrne, J, Calaminus, G, Lackner, H, Biondi, A, Oeffinger, K, Hudson, M, Skinner, R, Reaman, G, van der Pal, H, Kremer, L, Den Hartogh, J, Michel, G, Frey, E, Bardi, E, Hawkins, M, Rizvi, K, Terenziani, M, Valsecchi, M, Bode, G, Jenney, M, de Vathaire, F, Garwicz, S, Levitt, G, Grabow, D, Kuehni, C, Schrappe, M, Hjorth, L, APH - Quality of Care, Paediatric Oncology, ARD - Amsterdam Reproduction and Development, and CCA - Cancer Treatment and Quality of Life

Subjects
Adult, Male, 0301 basic medicine, Quality of life, medicine.medical_specialty, Adolescent, Statement (logic), education, Childhood cancer, Declaration, Childhood cure, Health informatics, 03 medical and health sciences, 0302 clinical medicine, Quality of life (healthcare), Cancer Survivors, Neoplasms, medicine, Humans, Childhood care, Survivors, Child, business.industry, Oncology (nursing), Public health, Cancer, medicine.disease, Oncology nursing, 030104 developmental biology, Oncology, Health, 030220 oncology & carcinogenesis, Family medicine, Female, business
Abstract

Purpose: The number of persons who have successfully completed treatment for a cancer diagnosed during childhood and who have entered adulthood is increasing over time, and former patients will become aging citizens. Methods: Ten years ago, an expert panel met in Erice, Italy, to produce a set of principles concerning the cure and care of survivors of childhood and adolescent cancer. The result was the Erice Statement (Haupt et al. Eur J Cancer 43(12):1778–80, 2007) that was translated into nine languages. Ten years on, it was timely to review, and possibly revise, the Erice Statement in view of the changes in paediatric oncology and the number and results of international follow-up studies conducted during the intervening years. Results: The long-term goal of the cure and care of a child with cancer is that he/she becomes a resilient and autonomous adult with optimal health-related quality of life, accepted in society at the same level as his/her age peers. “Cure” refers to cure from the original cancer, regardless of any potential for, or presence of, remaining disabilities or side effects of treatment. The care of a child with cancer should include complete and honest information for parents and the child. Conclusions and implication for cancer survivors: Some members of the previous expert panel, as well as new invited experts, met again in Erice to review the Erice Statement, producing a revised version including update and integration of each of the ten points. In addition, a declaration has been prepared, by the Childhood Cancer International Survivors Network in Dublin on October 2016 (see Annex 1).

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results